113 related articles for article (PubMed ID: 18418024)
1. Flumazenil in the treatment of dizziness and vegetative symptoms after intravenous infusion of paclitaxel.
Provencio M; Espinosa R; Sánchez A; España P
Onkologie; 2008 Apr; 31(4):203. PubMed ID: 18418024
[No Abstract] [Full Text] [Related]
2. [Taxol].
Kühnle H
Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
[No Abstract] [Full Text] [Related]
3. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
4. Scleroderma induced by paclitaxel.
Pedersen JV; Jensen S; Krarup-Hansen A; Riis L
Acta Oncol; 2010 Aug; 49(6):866-8. PubMed ID: 20446892
[No Abstract] [Full Text] [Related]
5. Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
Londhey VA; Parikh FS
J Assoc Physicians India; 2009 Apr; 57():342-3. PubMed ID: 19702043
[No Abstract] [Full Text] [Related]
6. Paclitaxel premedication regimens.
Boehm DK; Maksymiuk AW
J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
[No Abstract] [Full Text] [Related]
7. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
8. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer.
De Angelis R; Bugatti L; Cerioni A; Del Medico P; Filosa G
Clin Rheumatol; 2003 Feb; 22(1):49-52. PubMed ID: 12605319
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic ascites: taxol-induced hypersensitivity?
Kobayashi TK; Muramatsu M; Ueda M; Nishino T; Bamba M; Urabe M; Moritani S
Cytopathology; 2004 Jun; 15(3):171-2. PubMed ID: 15165278
[No Abstract] [Full Text] [Related]
10. Emergency. Chemotherapy-induced hypersensitivity reaction.
Myers JS; Kearney K
Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
[No Abstract] [Full Text] [Related]
11. Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
Mantovani G; Gramignano G; Mais V; Melis GB; Parodo G; Carrucciu GM
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):238-9. PubMed ID: 16698170
[No Abstract] [Full Text] [Related]
12. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.
McGuire WP
J Clin Oncol; 2009 Oct; 27(28):4633-4. PubMed ID: 19704055
[No Abstract] [Full Text] [Related]
14. [Safety evaluation of paclitaxel injection NK in adjuvant therapy for breast cancer].
Takahara S; Yamamoto H; Tokushima Y; Shiba E
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1851-6. PubMed ID: 19920387
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
[TBL] [Abstract][Full Text] [Related]
16. Continuous intravenous flumazenil infusion for benzodiazepine poisoning.
Brammer G; Gibly R; Walter FG; Bey T; Torres R; Kohler S
Vet Hum Toxicol; 2000 Oct; 42(5):280-1. PubMed ID: 11003118
[TBL] [Abstract][Full Text] [Related]
17. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Loven D; Levavi H; Sabach G; Zart R; Andras M; Fishman A; Karmon Y; Levi T; Dabby R; Gadoth N
Eur J Cancer Care (Engl); 2009 Jan; 18(1):78-83. PubMed ID: 19473225
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.
Penel N; Bui BN; Bay JO; Cupissol D; Ray-Coquard I; Piperno-Neumann S; Kerbrat P; Fournier C; Taieb S; Jimenez M; Isambert N; Peyrade F; Chevreau C; Bompas E; Brain EG; Blay JY
J Clin Oncol; 2008 Nov; 26(32):5269-74. PubMed ID: 18809609
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
[TBL] [Abstract][Full Text] [Related]
20. Case report of a generalized seizure related to Paclitaxel infusion.
Cronk M; Abraham R; Perrin L
J Natl Cancer Inst; 2004 Mar; 96(6):487. PubMed ID: 15026476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
